Is IMCR or BLTE more profitable?

Belite Bio has a net margin of 0.00% compared to Immunocore's net margin of -6.68%. Immunocore's return on equity of -7.07% beat Belite Bio's return on equity. Company Net Margins Return on Equity Return on Assets Immunocore -6.68% -7.07% -2.55% Belite Bio N/A -13.14% -12.88%

Does the media favor IMCR or BLTE?

In the previous week, Immunocore and Immunocore both had 3 articles in the media. Immunocore's average media sentiment score of 1.57 beat Belite Bio's score of 0.57 indicating that Immunocore is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunocore 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Belite Bio 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, IMCR or CGON?

Immunocore has higher revenue and earnings than CG Oncology. Immunocore is trading at a lower price-to-earnings ratio than CG Oncology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immunocore $400.02M 3.93 -$35.51M -$0.55 N/A CG Oncology $4.04M 1,571.01 -$160.99M -$2.33 N/A

Is IMCR or CGON more profitable?

CG Oncology has a net margin of 0.00% compared to Immunocore's net margin of -6.68%. Immunocore's return on equity of -7.07% beat CG Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Immunocore -6.68% -7.07% -2.55% CG Oncology N/A -23.33% -22.24%

Does the media prefer IMCR or CGON?

In the previous week, CG Oncology had 3 more articles in the media than Immunocore. MarketBeat recorded 6 mentions for CG Oncology and 3 mentions for Immunocore. Immunocore's average media sentiment score of 1.57 beat CG Oncology's score of 0.09 indicating that Immunocore is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunocore 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive CG Oncology 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor LEGN or IMCR?

In the previous week, Legend Biotech and Legend Biotech both had 3 articles in the media. Immunocore's average media sentiment score of 1.57 beat Legend Biotech's score of 0.63 indicating that Immunocore is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Legend Biotech 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immunocore 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Do analysts recommend RGC or IMCR?

Immunocore has a consensus target price of $56.71, indicating a potential upside of 83.66%. Given Immunocore's stronger consensus rating and higher probable upside, analysts clearly believe Immunocore is more favorable than Regencell Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Immunocore 1 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.56

Which has higher earnings & valuation, RGC or IMCR?

Regencell Bioscience has higher earnings, but lower revenue than Immunocore. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Regencell Bioscience N/A N/A -$3.58M N/A N/A Immunocore $400.02M 3.93 -$35.51M -$0.55 N/A

Does the media refer more to RGC or IMCR?

In the previous week, Regencell Bioscience had 11 more articles in the media than Immunocore. MarketBeat recorded 14 mentions for Regencell Bioscience and 3 mentions for Immunocore. Immunocore's average media sentiment score of 1.57 beat Regencell Bioscience's score of 0.08 indicating that Immunocore is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regencell Bioscience 0 Very Positive mention(s) 1 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Immunocore 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor TWST or IMCR?

In the previous week, Twist Bioscience had 10 more articles in the media than Immunocore. MarketBeat recorded 13 mentions for Twist Bioscience and 3 mentions for Immunocore. Immunocore's average media sentiment score of 1.57 beat Twist Bioscience's score of 0.13 indicating that Immunocore is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Twist Bioscience 4 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Immunocore 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Immunocore (IMCR) Competitors

$30.88 0.00 (0.00%)

Closing price 06/26/2026 04:00 PM Eastern

Extended Trading

$31.22 +0.34 (+1.11%)

As of 06/26/2026 06:41 PM Eastern

Compare

IMCR vs. BLTE, CGON, LEGN, RGC, and TWST

Should you buy Immunocore stock or one of its competitors? MarketBeat compares Immunocore with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Immunocore include Belite Bio (BLTE), CG Oncology (CGON), Legend Biotech (LEGN), Regencell Bioscience (RGC), and Twist Bioscience (TWST). These companies are all part of the "pharmaceutical products" industry.

How does Immunocore compare to Belite Bio?

Immunocore (NASDAQ:IMCR) and Belite Bio (NASDAQ:BLTE) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, profitability, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and risk.

Immunocore has higher revenue and earnings than Belite Bio. Belite Bio is trading at a lower price-to-earnings ratio than Immunocore, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunocore	$400.02M	3.93	-$35.51M	-$0.55	N/A
Belite Bio	N/A	N/A	-$77.61M	-$2.53	N/A

Belite Bio has a net margin of 0.00% compared to Immunocore's net margin of -6.68%. Immunocore's return on equity of -7.07% beat Belite Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunocore	-6.68%	-7.07%	-2.55%
Belite Bio	N/A	-13.14%	-12.88%

Immunocore has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market. Comparatively, Belite Bio has a beta of -1.24, meaning that its stock price is 224% less volatile than the broader market.

Immunocore presently has a consensus price target of $56.71, suggesting a potential upside of 83.66%. Belite Bio has a consensus price target of $203.00, suggesting a potential upside of 36.49%. Given Immunocore's higher probable upside, equities research analysts plainly believe Immunocore is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunocore	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56
Belite Bio	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

84.5% of Immunocore shares are owned by institutional investors. Comparatively, 0.5% of Belite Bio shares are owned by institutional investors. 10.1% of Immunocore shares are owned by insiders. Comparatively, 13.3% of Belite Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Immunocore and Immunocore both had 3 articles in the media. Immunocore's average media sentiment score of 1.57 beat Belite Bio's score of 0.57 indicating that Immunocore is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunocore	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Belite Bio	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Immunocore beats Belite Bio on 11 of the 15 factors compared between the two stocks.

How does Immunocore compare to CG Oncology?

Immunocore (NASDAQ:IMCR) and CG Oncology (NASDAQ:CGON) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and valuation.

In the previous week, CG Oncology had 3 more articles in the media than Immunocore. MarketBeat recorded 6 mentions for CG Oncology and 3 mentions for Immunocore. Immunocore's average media sentiment score of 1.57 beat CG Oncology's score of 0.09 indicating that Immunocore is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunocore	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
CG Oncology	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Immunocore has a beta of 0.74, suggesting that its share price is 26% less volatile than the broader market. Comparatively, CG Oncology has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market.

84.5% of Immunocore shares are owned by institutional investors. Comparatively, 26.6% of CG Oncology shares are owned by institutional investors. 10.1% of Immunocore shares are owned by company insiders. Comparatively, 4.8% of CG Oncology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

CG Oncology has a net margin of 0.00% compared to Immunocore's net margin of -6.68%. Immunocore's return on equity of -7.07% beat CG Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunocore	-6.68%	-7.07%	-2.55%
CG Oncology	N/A	-23.33%	-22.24%

Immunocore has higher revenue and earnings than CG Oncology. Immunocore is trading at a lower price-to-earnings ratio than CG Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunocore	$400.02M	3.93	-$35.51M	-$0.55	N/A
CG Oncology	$4.04M	1,571.01	-$160.99M	-$2.33	N/A

Immunocore presently has a consensus target price of $56.71, indicating a potential upside of 83.66%. CG Oncology has a consensus target price of $81.73, indicating a potential upside of 13.57%. Given Immunocore's higher possible upside, research analysts plainly believe Immunocore is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunocore	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56
CG Oncology	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

Summary

Immunocore beats CG Oncology on 11 of the 17 factors compared between the two stocks.

How does Immunocore compare to Legend Biotech?

Legend Biotech (NASDAQ:LEGN) and Immunocore (NASDAQ:IMCR) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends, media sentiment and valuation.

Legend Biotech presently has a consensus price target of $60.23, suggesting a potential upside of 109.94%. Immunocore has a consensus price target of $56.71, suggesting a potential upside of 83.66%. Given Legend Biotech's stronger consensus rating and higher probable upside, equities research analysts plainly believe Legend Biotech is more favorable than Immunocore.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Legend Biotech	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.67
Immunocore	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56

In the previous week, Legend Biotech and Legend Biotech both had 3 articles in the media. Immunocore's average media sentiment score of 1.57 beat Legend Biotech's score of 0.63 indicating that Immunocore is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Legend Biotech	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunocore	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

70.9% of Legend Biotech shares are owned by institutional investors. Comparatively, 84.5% of Immunocore shares are owned by institutional investors. 0.0% of Legend Biotech shares are owned by company insiders. Comparatively, 10.1% of Immunocore shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Legend Biotech has a beta of 0.35, suggesting that its share price is 65% less volatile than the broader market. Comparatively, Immunocore has a beta of 0.74, suggesting that its share price is 26% less volatile than the broader market.

Immunocore has lower revenue, but higher earnings than Legend Biotech. Immunocore is trading at a lower price-to-earnings ratio than Legend Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Legend Biotech	$1.03B	5.18	-$296.80M	-$0.68	N/A
Immunocore	$400.02M	3.93	-$35.51M	-$0.55	N/A

Immunocore has a net margin of -6.68% compared to Legend Biotech's net margin of -21.98%. Immunocore's return on equity of -7.07% beat Legend Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Legend Biotech	-21.98%	-24.92%	-14.87%
Immunocore	-6.68%	-7.07%	-2.55%

Summary

Immunocore beats Legend Biotech on 10 of the 16 factors compared between the two stocks.

How does Immunocore compare to Regencell Bioscience?

Regencell Bioscience (NASDAQ:RGC) and Immunocore (NASDAQ:IMCR) are both pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, media sentiment, valuation, dividends, earnings, institutional ownership and analyst recommendations.

Regencell Bioscience has a beta of 1.66, indicating that its stock price is 66% more volatile than the broader market. Comparatively, Immunocore has a beta of 0.74, indicating that its stock price is 26% less volatile than the broader market.

Regencell Bioscience has higher earnings, but lower revenue than Immunocore.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A
Immunocore	$400.02M	3.93	-$35.51M	-$0.55	N/A

In the previous week, Regencell Bioscience had 11 more articles in the media than Immunocore. MarketBeat recorded 14 mentions for Regencell Bioscience and 3 mentions for Immunocore. Immunocore's average media sentiment score of 1.57 beat Regencell Bioscience's score of 0.08 indicating that Immunocore is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regencell Bioscience	0 Very Positive mention(s)	1 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Immunocore	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

0.1% of Regencell Bioscience shares are owned by institutional investors. Comparatively, 84.5% of Immunocore shares are owned by institutional investors. 10.1% of Immunocore shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Regencell Bioscience has a net margin of 0.00% compared to Immunocore's net margin of -6.68%. Regencell Bioscience's return on equity of 0.00% beat Immunocore's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regencell Bioscience	N/A	N/A	N/A
Immunocore	-6.68%	-7.07%	-2.55%

Immunocore has a consensus target price of $56.71, indicating a potential upside of 83.66%. Given Immunocore's stronger consensus rating and higher probable upside, analysts clearly believe Immunocore is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Immunocore	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56

Summary

Immunocore beats Regencell Bioscience on 8 of the 14 factors compared between the two stocks.

How does Immunocore compare to Twist Bioscience?

Twist Bioscience (NASDAQ:TWST) and Immunocore (NASDAQ:IMCR) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, dividends, media sentiment and analyst recommendations.

Immunocore has a net margin of -6.68% compared to Twist Bioscience's net margin of -19.85%. Immunocore's return on equity of -7.07% beat Twist Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Twist Bioscience	-19.85%	-26.73%	-19.15%
Immunocore	-6.68%	-7.07%	-2.55%

Twist Bioscience currently has a consensus target price of $74.60, suggesting a potential downside of 25.28%. Immunocore has a consensus target price of $56.71, suggesting a potential upside of 83.66%. Given Immunocore's higher possible upside, analysts clearly believe Immunocore is more favorable than Twist Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Twist Bioscience	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Immunocore	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56

84.5% of Immunocore shares are owned by institutional investors. 3.1% of Twist Bioscience shares are owned by insiders. Comparatively, 10.1% of Immunocore shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Twist Bioscience has a beta of 2.23, meaning that its stock price is 123% more volatile than the broader market. Comparatively, Immunocore has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market.

Immunocore has higher revenue and earnings than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Immunocore, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Twist Bioscience	$376.57M	16.51	-$77.67M	-$1.33	N/A
Immunocore	$400.02M	3.93	-$35.51M	-$0.55	N/A

In the previous week, Twist Bioscience had 10 more articles in the media than Immunocore. MarketBeat recorded 13 mentions for Twist Bioscience and 3 mentions for Immunocore. Immunocore's average media sentiment score of 1.57 beat Twist Bioscience's score of 0.13 indicating that Immunocore is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Twist Bioscience	4 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Immunocore	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Immunocore beats Twist Bioscience on 12 of the 17 factors compared between the two stocks.

Get Immunocore News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMCR vs. The Competition

Export

Metric	Immunocore	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.57B	$3.62B	$6.83B	$12.17B
Dividend Yield	N/A	2.21%	2.66%	6.11%
P/E Ratio	-56.14	21.75	26.14	24.17
Price / Sales	3.93	334.26	555.66	102.83
Price / Cash	N/A	62.10	29.09	36.93
Price / Book	4.11	8.31	10.78	6.38
Net Income	-$35.51M	$23.92M	$3.58B	$337.00M
7 Day Performance	5.21%	1.93%	1.97%	-0.20%
1 Month Performance	6.89%	-0.41%	-0.24%	-1.40%
1 Year Performance	-0.77%	65.22%	34.39%	27.76%

Immunocore Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMCR Immunocore	3.1382 of 5 stars	$30.88 flat	$56.71 +83.7%	-0.8%	$1.57B	$400.02M	N/A	320	Positive News
BLTE Belite Bio	3.254 of 5 stars	$146.14 -0.6%	$203.00 +38.9%	+151.9%	$5.90B	N/A	N/A	10
CGON CG Oncology	2.0806 of 5 stars	$65.50 -1.1%	$81.73 +24.8%	+177.3%	$5.78B	$4.04M	N/A	61	Positive News Gap Up
LEGN Legend Biotech	4.0323 of 5 stars	$29.75 +1.4%	$60.23 +102.5%	-17.2%	$5.53B	$1.03B	N/A	2,965	Gap Down
RGC Regencell Bioscience	0.2897 of 5 stars	$11.15 +6.0%	N/A	-62.8%	$5.51B	N/A	N/A	10	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMCR) was last updated on 6/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Immunocore (IMCR) Competitors

IMCR vs. BLTE, CGON, LEGN, RGC, and TWST

How does Immunocore compare to Belite Bio?

Summary

How does Immunocore compare to CG Oncology?

Summary

How does Immunocore compare to Legend Biotech?

Summary

How does Immunocore compare to Regencell Bioscience?

Summary

How does Immunocore compare to Twist Bioscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMCR vs. The Competition

Immunocore Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Immunocore (IMCR) Competitors

IMCR vs. BLTE, CGON, LEGN, RGC, and TWST

How does Immunocore compare to Belite Bio?

Which has preferable valuation and earnings, IMCR or BLTE?

Is IMCR or BLTE more profitable?

Which has more volatility and risk, IMCR or BLTE?

Do analysts prefer IMCR or BLTE?

Do institutionals & insiders have more ownership in IMCR or BLTE?

Does the media favor IMCR or BLTE?

Summary

How does Immunocore compare to CG Oncology?

Does the media prefer IMCR or CGON?

Which has more volatility & risk, IMCR or CGON?

Do institutionals & insiders believe in IMCR or CGON?

Is IMCR or CGON more profitable?

Which has stronger earnings and valuation, IMCR or CGON?

Do analysts rate IMCR or CGON?

Summary

How does Immunocore compare to Legend Biotech?

Do analysts prefer LEGN or IMCR?

Does the media favor LEGN or IMCR?

Do insiders and institutionals hold more shares of LEGN or IMCR?

Which has more risk and volatility, LEGN or IMCR?

Which has preferable earnings and valuation, LEGN or IMCR?

Is LEGN or IMCR more profitable?

Summary

How does Immunocore compare to Regencell Bioscience?

Which has more risk and volatility, RGC or IMCR?

Which has higher earnings & valuation, RGC or IMCR?

Does the media refer more to RGC or IMCR?

Do insiders & institutionals have more ownership in RGC or IMCR?

Is RGC or IMCR more profitable?

Do analysts recommend RGC or IMCR?

Summary

How does Immunocore compare to Twist Bioscience?

Is TWST or IMCR more profitable?

Do analysts recommend TWST or IMCR?

Do institutionals & insiders hold more shares of TWST or IMCR?

Which has more risk & volatility, TWST or IMCR?

Which has higher valuation and earnings, TWST or IMCR?

Does the media favor TWST or IMCR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMCR vs. The Competition

Immunocore Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools